MK-1084

• UNSPSC Description:

  MK-1084 is a selective KRAS G12C inhibitor that is currently in Phase I clinical trial (NCT05067283). MK-1084 exhibits anticancer activity and can be used either alone or in combination with pembrolizumab (HY-P9902) for cancer research[1].

• Target Antigen:

  Ras

• Type:

  Reference compound

• Related Pathways:

  GPCR/G Protein;MAPK/ERK Pathway

• Applications:

  Cancer-Kinase/protease

• Field of Research:

  Cancer

• Assay Protocol:

  https://www.medchemexpress.com/mk-1084.html

• Solubility:

  DMSO : 100 mg/mL (ultrasonic)

• Smiles:

  FC1=C2C(OCCOC3=CC=NC(C(C)C)=C3N4C5=NC2=C(Cl)C=C5C(N6[C@@H](C)CN(C(C=C)=O)[C@H](C)C6)=NC4=O)=C(F)C=C1

• Molecular Weight:

  637.08

• References & Citations:

  [1]Rojas C, et al. 663P Safety and preliminary efficacy of the KRAS G12C inhibitor MK-1084 in solid tumors and in combination with pembrolizumab in NSCLC[J]. Annals of Oncology, 2023, 34: S466-S467.

• Shipping Conditions:

  Room Temperature

• Clinical Information:

  Phase 3

• CAS Number:

  2641216-67-1